Extent of Resection in Meningioma: Predictive Factors and Clinical Implications.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
11 04 2019
Historique:
received: 15 11 2018
accepted: 13 03 2019
entrez: 13 4 2019
pubmed: 13 4 2019
medline: 2 10 2020
Statut: epublish

Résumé

Meningiomas present as intracranial extra-axial lesions with dural attachment, which are primarily managed surgically. The extent of resection (EOR) may vary depending on patient- and tumor-related factors. The aim of this study is to identify preoperative predictive factors of EOR and to propose an estimation of the predicted gross total resection (GTR) based of patient- and tumor-characteristics. 1469 patients from a retrospectively (1990 to 2002) and prospectively managed (2003 to 2010) databank of Oslo University Hospital, Norway, totalling 11,414 patient-years of follow-up were included. Patients had a mean age at surgery of 64 ± 20.1 years with a female-to-male ratio was 2.4:1 and a mean KPS of 81.2 ± 12.1. Skull-base meningiomas represented 47% of all cases. WHO grades were I in 92.3%, II in 5.2%, and III in 2.2%. Bone infiltration was described in 18.7% of cases. 39.3% of patients had Simpson I resection, 34.3% had Simpson II, 5.4% had Simpson III, 20.6% had Simpson IV, and 0.5% had Simpson V. The risk factors for incomplete resection were: symptomatic presentation (OR 0.56 [0.43-0.72]), skull-base location (OR 0.79 [0.70-0.88]), and bone invasion (OR 0.85 [0.73-0.99]). Using a recursive partitioning analysis, we propose a classification-tree for the prediction of GTR rate based on preoperatively determinable patient- and tumor characteristics. The identification of preoperative predictors of poor GTR rate may aid clinicians managing meningioma patients. In selected cases were the predicted GTR rate is low, staged treatment with surgical debulking followed by adjuvant therapy may be favored in order to minimize postoperative morbidity and mortality.

Identifiants

pubmed: 30976047
doi: 10.1038/s41598-019-42451-z
pii: 10.1038/s41598-019-42451-z
pmc: PMC6459829
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5944

Références

Lancet Oncol. 2016 Sep;17(9):e383-91
pubmed: 27599143
J Neurol Neurosurg Psychiatry. 1997 Apr;62(4):341-5
pubmed: 9120445
Clin Neurol Neurosurg. 2013 Aug;115(8):1527-9
pubmed: 23290420
J Neurosurg. 1983 Jan;58(1):51-6
pubmed: 6847909
Neurosurg Rev. 2019 Mar;42(1):163-173
pubmed: 29627874
Radiat Oncol. 2012 Dec 29;7:226
pubmed: 23273161
J Neurosurg. 2014 Apr;120(4):827-32
pubmed: 24484230
Clin Neurol Neurosurg. 2016 Feb;141:117-21
pubmed: 26780494
Skull Base. 2007 May;17(3):157-71
pubmed: 17973029
J Neurooncol. 2017 Jul;133(3):641-651
pubmed: 28527009
Neurosurg Rev. 2017 Jan;40(1):163-169
pubmed: 27553846
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):859-64
pubmed: 22137023
J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39
pubmed: 13406590
World Neurosurg. 2018 Apr;112:e145-e156
pubmed: 29317363
Neuro Oncol. 2016 Oct 1;18(suppl_5):v1-v75
pubmed: 28475809
Laryngoscope. 2007 Oct;117(10):1710-9
pubmed: 17690614
J Neurosurg. 2012 Dec;117(6):999-1006
pubmed: 23061394
Neurosurgery. 2017 Aug 1;81(2):297-306
pubmed: 28327947
Acta Neurochir (Wien). 2018 Sep;160(9):1801-1812
pubmed: 29974236
J Neurosurg. 2016 Sep;125(3):551-60
pubmed: 26824369
World Neurosurg. 2018 Jan;109:e588-e593
pubmed: 29042332
Neurosurg Rev. 2019 Dec;42(4):961-972
pubmed: 29978438
World Neurosurg. 2018 Nov;119:e589-e597
pubmed: 30081236
J Neurosurg. 2018 Nov 1;129(5):1240-1248
pubmed: 29350599
Neurochirurgie. 2018 Mar;64(1):15-21
pubmed: 26073920
Epilepsy Behav. 2018 Nov;88:146-151
pubmed: 30269033
Cancer. 2018 Feb 15;124(4):734-742
pubmed: 29131312
J Neurosurg. 2017 Jan;126(1):201-211
pubmed: 27058201
J Neurol Surg B Skull Base. 2016 Jun;77(3):219-25
pubmed: 27175316
Neurosurg Focus. 2007;23(4):E6
pubmed: 17961043
Clin Neurol Neurosurg. 2014 Sep;124:123-6
pubmed: 25043442
World Neurosurg. 2016 Dec;96:483-488
pubmed: 27637164
PLoS One. 2018 Oct 16;13(10):e0202520
pubmed: 30325925

Auteurs

Jean-Michel Lemée (JM)

Department of Clinical Neurosciences, Division of Neurosurgery, Geneva University Hospitals, Genève, Switzerland. Jean-Michel.Lemee@hcuge.ch.

Marco V Corniola (MV)

Department of Clinical Neurosciences, Division of Neurosurgery, Geneva University Hospitals, Genève, Switzerland.

Michele Da Broi (M)

Faculty of Medicine, University of Oslo, Oslo, Norway.

Holger Joswig (H)

Department of Clinical Neurosciences, Division of Neurosurgery, Geneva University Hospitals, Genève, Switzerland.

David Scheie (D)

Section of Neuropathology, Rigshospitalet, Copenhagen, Denmark.

Karl Schaller (K)

Department of Clinical Neurosciences, Division of Neurosurgery, Geneva University Hospitals, Genève, Switzerland.
Faculty of Medicine, University of Geneva, Genève, Switzerland.

Eirik Helseth (E)

Faculty of Medicine, University of Oslo, Oslo, Norway.
Department of Neurosurgery, Oslo University Hospital, Oslo, Norway.

Torstein R Meling (TR)

Department of Clinical Neurosciences, Division of Neurosurgery, Geneva University Hospitals, Genève, Switzerland.
Faculty of Medicine, University of Oslo, Oslo, Norway.
Faculty of Medicine, University of Geneva, Genève, Switzerland.
Department of Neurosurgery, Oslo University Hospital, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH